Founded by Dr. Mark Moran in 1997, Intarcia Therapeutics is enagaged in developing therapies to ensure the best treatment outcome by optimizing patient convenience and adherence. Intarcia is addressing challenging diseases that require long-term chronic therapy by enhancing efficacy and reducing the burden therapies often place on the patient's life. Intarcia's drug development expertise and competitive edge is demonstrated by its ability to stabilize macromolecules and to deliver them in a constant and consistent manner over an extended period of time via the proprietary DUROS® drug delivery platform.